Composition, form of production and packaging
Eye drops 0.01% as a colorless, clear liquid.
100 ml
benzyldimethyl [3-myristoylamino) propyl] ammonium chloride monohydrate (in terms of anhydrous substance) 0.01 g
Excipients: sodium chloride - 0.9 g, purified water - up to 100 ml.
5 ml - polymeric bottles with a stopper-dropper (1) - packs cardboard.
10 ml - polymer bottles capped with stopper-dropper and cap screwed with the control of the first opening (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
PHARMACHOLOGIC EFFECT
Antiseptic preparation for topical application in ophthalmology.
Has a pronounced antimicrobial effect against Gram-positive and Gram-negative, aerobic and anaerobic bacteria in the form of monocultures and microbial associations, including hospital strains with multidrug resistance to antibiotics.
It is active against chlamydia, pathogenic fungi, as well as against herpes viruses, adenoviruses.
The drug is more effective against gram-positive bacteria, including. staphylococci, streptococci.
The drug reduces the resistance of bacteria and fungi to antibiotics.
PHARMACOKINETICS
Data on the pharmacokinetics of Ocomistin В® are not available.
INDICATIONS
- Acute and chronic conjunctivitis;
- Blepharoconjunctivitis;
- keratitis;
- keratouveitis;
- prevention of purulent-inflammatory complications in the preoperative and postoperative period;
- trauma to the eye;
- Treatment of bacterial conjunctivitis in children over the age of 3 years.
DOSING MODE
With a therapeutic purpose , Ocomistin В® is instilled in the conjunctival sac by 1-2 drops 4-6 times / day until a clinical recovery.
With the preventive purpose the drug is instilled for 2-3 days before the operation, and also within 10-15 days after the operation, 1-2 drops 3 times / day.
In pediatric practice, for treatment of bacterial conjunctivitis in children over the age of 3 years, Okikistin В® is instilled in the conjunctival sac by 1 drop up to 6 times / day for 7-10 days.
SIDE EFFECT
Possible: allergic reactions.
In some cases: a slight burning sensation, discomfort, which pass independently after 15-20 seconds and do not require drug withdrawal.
CONTRAINDICATIONS
- Children under 3 years of age (only for indication of bacterial conjunctivitis;
- Children under 18 years of age (for all other indications);
- Pregnancy;
- the period of lactation (breastfeeding);
- Hypersensitivity to the components of the drug.
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
SPECIAL INSTRUCTIONS
Contact lenses should be removed immediately before instillation of Ocomistin В® and should not be worn before 15 minutes after instillation.
Impact on the ability to drive vehicles and manage mechanisms
During the treatment period, it is necessary to refrain from driving vehicles and from engaging in other potentially hazardous activities requiring increased concentration of attention, rapidity of psychomotor reactions and good vision, within 30 minutes after instillation into the eye.
OVERDOSE
Data on the overdose of Ocomistin В® are not available.
DRUG INTERACTION
Studies of the interaction of Ocomistin В® with other drugs have not been conducted.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years. Shelf life after bottle opening - 1 month.
